Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

INTRODUCTION: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype have not been systematically described. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhury, Noura J., Schneider, Jaime L., Patil, Tejas, Zhu, Viola W., Goldman, Debra A., Yang, Soo-Ryum, Falcon, Christina J., Do, Andrew, Nie, Yunan, Plodkowski, Andrew J., Chaft, Jamie E., Digumarthy, Subba R., Rekhtman, Natasha, Arcila, Maria E., Iasonos, Alexia, Ou, Sai-Hong I., Lin, Jessica J., Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474494/
https://www.ncbi.nlm.nih.gov/pubmed/34590036
http://dx.doi.org/10.1016/j.jtocrr.2021.100187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474494/
https://www.ncbi.nlm.nih.gov/pubmed/34590036
http://dx.doi.org/10.1016/j.jtocrr.2021.100187

Ejemplares similares